Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21311603 | 0.92 | SLC6A2 (0.50) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL21294673 | 0.78 | SLC6A2 (0.43) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL9870878 | 0.78 | SLC6A2 (0.58) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL23639056 | 0.77 | SCN9A (0.43) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL21311609 | 0.76 | SCN9A (0.40) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL735510 | 0.75 | SPHK1 (0.44) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL736152 | 0.74 | SLC6A2 (0.47) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL16536436 | 0.74 | SLC6A2 (0.47) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL16536421 | 0.74 | SLC6A2 (0.47) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL16543148 | 0.74 | SLC6A2 (0.47) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138377-B2 | Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use | DOV PHARMACEUTICAL, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20080293822-A1 | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use | ETHISMOS RESEARCH, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080269348-A1 | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use | ETHISMOS RESEARCH, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080194696-A1 | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use | ETHISMOS RESEARCH, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194696-A1 | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use | HTR2C, HTR1B, HTR3C | SLC6A4 93/4885SLC6A2 150/4885SLC6A3 76/4885 |
| US-20080293822-A1 | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use | HTR2C, HTR1B, HTR3C | SLC6A4 93/4885SLC6A2 150/4885SLC6A3 76/4885 |
| US-20080269348-A1 | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use | HTR2C, HTR1B, HTR3C | SLC6A4 93/4885SLC6A2 150/4885SLC6A3 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.